Unraveling the Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic and Potential Therapeutic Implications
, Alexandra Papoudou-Bai 2, Konstantina Papathanasiou 1, Evangelos Kolettas 3,4, Panagiotis Kanavaros 5,†and Eleftheria Hatzimichael 1,*,†Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThe review describes the role of the immune environment in the development and progression of DLBCL. The article is well-written and of interest to experts in the field. Some minor issues can be corrected in a revised version of the manuscript.
Figures 1 and 2: I suggest to combine both figures in one new bigger Figure 1, possibly subdivided as Figure 1A) and 1B).
Figure 3: Please add a blank space after the comma in ´´IL-10,IL-13´´ and ´´IL-4,IL-10´´. Replace ´´interleukin´´ by ´´Interleukin´´ in the caption.
Line 445: Please remove the dot before ´´(114)´´.
Section 4, Immune evasion: Please mention the epigenetic drugs in clinical studies with DLBCL patients. In addition, I miss HDAC inhibition on the list of possible immune evasion preventing mechanisms. Are HDACs less relevant in DLBCL? Maybe the authors can comment or discuss.
Comments on the Quality of English Languagen.a.
Author Response
|
Thank you very much for taking the time to review this manuscript. Please find the detailed responses below and the corresponding corrections highlighted in the re-submitted files. |
Comment 1: Figures 1 and 2: I suggest to combine both figures in one new bigger Figure 1, possibly subdivided as Figure 1A) and 1B).
Response 1: We would like to thank the reviewer for this comment. We have now merged Figure 1 and Figure 2 into one figure as suggested.
Comment 2: Figure 3: Please add a blank space after the comma in ´´IL-10,IL-13´´ and ´´IL-4,IL-10´´. Replace ´´interleukin´´ by ´´Interleukin´´ in the caption.
Response 2: Thank you for the comment. We have made the changes. In the revised manuscript Figure 3 is now Figure 2.
Comment 3: Line 445: Please remove the dot before ´´(114)´´.
Response 3: Thank you for this comment, this has been changed accordingly.
Comment 4: Section 4, Immune evasion: Please mention the epigenetic drugs in clinical studies with DLBCL patients. In addition, I miss HDAC inhibition on the list of possible immune evasion preventing mechanisms. Are HDACs less relevant in DLBCL? Maybe the authors can comment or discuss
Response 4: Thank you for pointing this out. In the revised manuscript we have entered information from clinical studies regarding epigenetic drugs. Moreover, we have added a paragraph regarding HDAC inhibition and its potential efficacy in DLBCL patients [Lines 443-460].
Reviewer 2 Report
Comments and Suggestions for Authors
The manuscript “Unraveling the Immune Microenvironment in Diffuse Large B- Cell Lymphoma: Prognostic and Therapeutic Implications," cimb-3066110, reviews up-to-date information on the microenvironment in DLBCL. The paper is written very well; it is easy to follow and contains some interesting observations and summaries. Therefore, I recommend its publication after a few minor comments:
- This is a review type of manuscript. Therefore, please ensure that all the coauthors have sufficient self-citation, particularly in cases of DLBCL disease.
- I recommend merging Figure 1 and Figure 2 and avoiding doubling titles.
- Better highlight the therapeutic approaches for DLBCL (known and potential), as this section is also included in the manuscript's title.
Author Response
|
Thank you very much for taking the time to review this manuscript. Please find the detailed responses below and the corresponding corrections highlighted in the re-submitted files. |
Comment 1: This is a review type of manuscript. Therefore, please ensure that all the coauthors have sufficient self-citation, particularly in cases of DLBCL disease.
Response 1: Thank you for this comment. Taking your comment into account we added 2 more self-citations, particularly for DLBCL disease. Specifically lines 63-65, reference 10, and lines 116-119, reference 18. Two of the coauthors (Ep.K. and K.P. are young investigators who work on tumor microenvironment in DLBCL and other lymphomas as a part of their PhD research, therefore they do not have previous work on it).
Comment 2: I recommend merging Figure 1 and Figure 2 and avoiding doubling titles
Response 2: Thank you for this suggestion. We have merged Figure 1 and Figure 2 into one Figure.
Comment 3: Better highlight the therapeutic approaches for DLBCL (known and potential), as this section is also included in the manuscript's title.
Response 3: Thank you for pointing this out. We added a paragraph regarding the approved treatment options in introduction. [Lines: 109-119]
Since there is no approved therapeutic agent targeting tumor microenvironment in DLBCL we have changed the title adding the word “potential”. To highlight potential therapeutic approaches for DLBCL we added a table with certain potential therapeutic agents who target TME in DLBCL (Table 2).
